1. Home
  2. LEGT vs ALEC Comparison

LEGT vs ALEC Comparison

Compare LEGT & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Legato Merger Corp. III

LEGT

Legato Merger Corp. III

N/A

Current Price

$11.09

Market Cap

285.6M

Sector

N/A

ML Signal

N/A

Logo Alector Inc.

ALEC

Alector Inc.

HOLD

Current Price

$2.07

Market Cap

268.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEGT
ALEC
Founded
2023
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
285.6M
268.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
LEGT
ALEC
Price
$11.09
$2.07
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.83
AVG Volume (30 Days)
115.7K
550.6K
Earning Date
02-19-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$21,045,000.00
Revenue This Year
N/A
$2.03
Revenue Next Year
N/A
$29.87
P/E Ratio
$35.64
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.57
$1.09
52 Week High
$11.94
$3.40

Technical Indicators

Market Signals
Indicator
LEGT
ALEC
Relative Strength Index (RSI) 55.64 40.88
Support Level $10.81 $1.91
Resistance Level $11.12 $2.62
Average True Range (ATR) 0.10 0.15
MACD -0.00 -0.03
Stochastic Oscillator 10.57 10.79

Price Performance

Historical Comparison
LEGT
ALEC

About LEGT Legato Merger Corp. III

Legato Merger Corp III is a blank check company.

About ALEC Alector Inc.

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Share on Social Networks: